Dalbavantsin - novaya vozmozhnost' v lechenii infektsiy kozhi i myagkikh tkaney, vyzvannykh rezistentnym Staphylococcus aureus
- Authors: Ushkalova E.A1, Korovyakova E.A1
-
Affiliations:
- Issue: No 18 (2014)
- Pages: 32-36
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/287488
- ID: 287488
Cite item
Abstract
Starting from the 2000s, infections caused by MRSA (Methicillin-Resistant Staphylococcus aureus) ceased to be exclusively nosocomial problem due to wide occurrence. The development of new antibiotics active against MRSA is a very urgent task. In the USA in May 2014, for the treatment of infections of the skin and soft tissue caused by Gram-positive organisms, including MRSA, new antibiotic -dalbavancin, a semisynthetic lypoglycopeptide, was released. Despite the favorable tolerability demonstrated in clinical studies, experts have expressed concerns about the safety of this drug, and warn against the off-label use of drug, for example in bacteremia or pneumonia. Apparently, the benefit/risk ratio of dalbavancin should be determined by its application in general medical practice.
Full Text
References
- Pope S.D., Roecker A.M. Dalbavancin: a novel lipoglycopeptide antibacterial. Pharmacotherapy. 2006;26;908-18.
- Rasigade J.P., Dumitrescu O., Lina G. New epidemiology of Staphylococcus aureus infections. Clin. Microbiol. infect. 2014 Jun 14. [Epub ahead of print].
- Boucher H. W. Challenges in anti-infective development in the era of bad bugs, no drugs: A regulatory perspective using the example of bloodstream infection as an indication. Clin. infectious Dis. 2010;50:S4-9.
- Appelbaum P.C. MRSA--the tip of the iceberg. Clin. Microbiol, infect. 2006;12(Suppl2):3-10.
- Szekely E., Lorinczi L., Bilca D., et al. incidence, antibiotic resistance and clonal relations of MRSA strains isolated from a Romanian university hospital. Acta Microbiol immunol Hung 2008;55:1-13.
- Cowcroft N., Duckworth G., Griffiths C., et al. Deaths involving MRSA: England and Wales, 1993-2006. Health Stat Q. 2008;37:57-6.
- Klevens R.M., Edwards J.R., Tenover F.C., et al. Changes in the epidemiology of methicillinresistant Staphylococcus aureus in intensive care units in U.S. hospitals, 1992-2003. Clin. infect. Dis. 2006;42:389-91.
- Köck R., Becker K., Cookson B., et al. Methicillinresistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill. 2010;15(41):19688.
- National nosocomial infections surveillance (NNiS) system report, data summary from January 1992 through June 2004 issued October 2004. Am. J. infect. Control. 2004;32:470-85. infect Control Hosp Epidemiol. 2008;29(11):996-1011.
- Hidron A.i., Edwards J.R., Patel J., et al. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007.
- Klevens R.M., Morrison M.A., Nadle J. invasive methicillin -resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298(15): 1763-71.
- Boucher H.W., Corey G.R. Epidemiology of methicillin -resistant Staphylococcus aureus. Clin. infect. Dis. 2008;46(Suppl 5):S344-49.
- Ohlsen К. Novel Antibiotics for the Treatment of Staphylococcus aureus. Expert Rev. Clin. Pharmacol. 2009;2(6):661-72.
- Stefani S., Chung D.R., Lindsay J.A., Friedrich A.W., Kearns A.M., et al. Methicillin-resistant Staphylococcus aureus (MRSA): Global epidemiology and harmonisation of typing methods. Int. J. Antimicrob Agents. 2012;39:273-82.
- Zetola N, Francis J.S., Nuermberger E.L., Bishai W.R. Community-acquired methicillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect. Dis 2005;5:275-86.
- Roberts J.C., Krueger R.L., Peak K.K., et al. Community-associated methicillin-resistant Staphylococcus aureus epidemic clone USA300 in isolates from Florida and Washington. J.Clin. Microbiol. 2006;44(1 ):225-26.
- Miller L.G., Perdreau-Remington F., Rieg G., et al. Necrotizing fasciitis caused by community-associated methicillin-resistant: Staphylococcus aureus in Los Angeles. N. Engl. J. Med. 2005;352(14):1445-53.
- Dominguez T.J. It's not a spider bite, it's community-acquired methicillin-resistant Staphylococcus aureus. J. Am. Board.Family Pract. 2004;17(3):220-26.
- Heymann W.R. Community-acquired methicillin-resistant Staphylococcus aureus infection. J.the Am. Acad. Dermatol. 2005;53(2):318-19.
- Weber J.T. Community-associated methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 2005;41(supplement 4) :S269-72.
- Pantosti A. Methicillin-resistant Staphylococcus aureus associated with animals and its relevance to human health. Front Microbiol. 2012;3:127.
- Graveland H., Duim B., van Duijkeren E., Heederik D., Wagenaar J.A. Livestock-associated methicillin-resistant Staphylococcus aureus in animals and humans. Int. J. Med. Microbiol. 2011;301:630-34.
- Himsworth C.G., Parsons K.L., Jardine C., Patrick D.M. Rats, cities, people, and pathogens: A systematic review and narrative synthesis of literature regarding the epidemiology of rat-associated zoonoses in urban centers. Vector Borne Zoonotic Dis. 2013;13:349-59.
- Himsworth C.G., Miller R.R., Montoya V., et al. Carriage of methicillin-resistant Staphylococcus aureus by wild urban Norway rats (Rattus norvegicus). PLoS One. 2014;9(2):e87983.
- European Food Safety Authority: Analysis of the baseline survey on the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in holding with breeding pigs in the EU, 2008, Part A: MRSA prevalence estimates. EFSA Journal. 2009;7:1376.
- Spoor L.E., McAdam P.R., Weinert L.A., et al. Livestock origin for a human pandemic clone of community-associated methicillin-resistant Staphylococcus aureus. MBio. 2013;4(4): pii: e00356-13.
- Gordon R.J., Lowy F.D. Pathogenesis of methicillin-resistant Staphylococcus aureus infection. Clin. Infect. Dis. 2008;46(Suppl. 5):S350-59.
- Cosgrove S.E., Sakoulas G., Perencevich E.N., et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin. Infect. Dis. 2003;36:53-59.
- Shurland S., Zhan M., Bradham D.D., Roghmann M.C. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 2007;28:273-79.
- Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol. 2005;26:166-74.
- Zahar J.R., Clech C., Tafflet M., et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia? Clin. Infect. Dis. 2005;41:1224-31.
- Engemann J.J., Carmeli Y., Cosgrove S.E., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 2003;36:592-98.
- Wilcox MH. MRSA new treatments on the horizon: current status. Injury. 2011;42(Suppl 5):S42-4.
- Projan S.J. Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 2003;6:427-30.
- Witte W., Cuny C., Klare I., Nubel U., Strommenger B., Werner G. Emergence and spread of antibiotic-resistant Gram-positive bacterial pathogens. Int. J. Med. Microbiol. 2008;298:365-77.
- Gardete S., Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J. Clin. Invest. 2014;124(7):2836-40.
- Дехнич А.В. Выявление резистентности к метициллину и другим лактамным антибиотикам методом скрининга: Метод. рекомендации для микробиологов. http://www.antibiotic.ru/rus/all/ metod/meticres.
- O'Brien D.J., Gould I.M. Does vancomycin have a future in the treatment of skin infections? Curr. Opin. Infect. Dis. 2014;27(2):146-54.
- Dalbavancin: New Option for Skin and Skin Structure Infections. Medscape. May 23, 2014.
- Pfizer Inc. Pfizer receives approvable letter from FDA for dalbavancin. December 21, 2007. http:// mediaroom.pfizer.com/portal/site/pfizer/index. jsp?ndmViewId=news_view&newsId=20071221005 672&newsLang=en.
- Pfizer Inc. Pfizer will withdraw global marketing applications for dalbavancin to conduct a new trial. September 6, 2008.www.pfizer.be/Media/Press+bulletins/Rese arch+and+development+and+business+developme nt/Withdraw+dalbavancin+market+applications.htm.
- Zhanel G.G., Calic D., Schweizer F., et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010;70:859-86.
- Bailey J., Summers K.M. Dalbavancin: a new lipoglycopeptide antibiotic. Am. J. Health Syst. Pharm. 2008;65:599-610.
- Burke S.L., Rose W.E. New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections. Expert Opin Pharmacother. 2014;15(4): 483-91.
- Buckwalter M., Dowell J.A. Population pharmacokinetic analysis of dalbavancin a novel lipoglycopeptide. J. Clin Pharmacol. 2005;45:1279-87.
- Raad, Darouiche R., Vazquez J., et al. Efficacy and safety of weekly dalbavancin therapy for catheter related bloodstream infection caused by gram-positive pathogens. Clin. Infect. Dis. 2005;40:374-80.
- Boucher H.W., Wilcox M., Talbot G.H., et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N. Engl. J. Med. 2014;370(23):2169-79.
- US Food and Drug Administration. FDA Briefing Document. Anti-infective Drugs Advisory Committee Meeting. March 31, 2014. http:// www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM390792.pdf Accessed May 16, 2014.
- Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis. 2005;41(10):1407-15.
- Chambers H.F. Pharmacology and the Treatment of Complicated Skin and Skin-Structure Infections. N. Engl. J. Med. 2014;370:2238-39. Dalbavancin, Oritavancin Safe, Effective for Skin Infection. Medscape. Jun 06, 2014.
- US Food and Drug Administration. FDA Briefing Document. Anti-infective Drugs Advisory Committee Meeting. March 31, 2014. http:// www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM390792.pdf Accessed May 16, 2014
- Dalbavancin, Oritavancin Safe, Effective for Skin Infection. Medscape. Jun 06, 2014.
- New Antibiotic Tedizolid (Sivextro) Approved by FDA. Medscape. Jun 20, 2014.